Applied Therapeutics logo.jpg
Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia
September 18, 2024 07:00 ET | Applied Therapeutics
- Company completed Late-Cycle review meeting with FDA - FDA no longer intends to hold Advisory Committee meeting - FDA Review of NDA continues to proceed as planned with PDUFA target action date of...
Applied Therapeutics logo.jpg
Applied Therapeutics to Participate in Upcoming Investor Conferences
September 04, 2024 07:00 ET | Applied Therapeutics
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics logo.jpg
Applied Therapeutics Reports Second Quarter 2024 Financial Results
August 07, 2024 07:00 ET | Applied Therapeutics
NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in early Q1...
Applied Therapeutics logo.jpg
Applied Therapeutics Added to Russell 3000® Index
July 01, 2024 07:00 ET | Applied Therapeutics
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics logo.jpg
Applied Therapeutics Reports First Quarter 2024 Financial Results
May 09, 2024 07:00 ET | Applied Therapeutics
Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024 Govorestat MAA under review by EMA; Day 120 3-month clock-stop extension granted; decision...
Applied Therapeutics logo.jpg
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024 07:00 ET | Applied Therapeutics
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics logo.jpg
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
April 15, 2024 07:00 ET | Applied Therapeutics
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics logo.jpg
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
April 04, 2024 07:00 ET | Applied Therapeutics
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics logo.jpg
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
March 28, 2024 16:30 ET | Applied Therapeutics
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics logo.jpg
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
March 06, 2024 07:00 ET | Applied Therapeutics
NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review by EMA with decision expected in...